Amgen said Sunday that patients with advanced lung cancer who were given its drug to block a protein called KRAS lived for a median of six months without their tumors worsening. That’s a measure of response durability that experts say could be strong enough to secure the drug’s approval — if replicated in a larger clinical trial that will read out later this year.
But the Amgen drug, a pill called sotorasib (formerly known as AMG 510) showed partial tumor shrinkage in just over one-third of the lung cancer patients enrolled in the trial. That’s down from a 50% partial response rate reported last year in the same study.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Pancreatic adenocarcinoma frequently has KRAS mutations, but I gather that they typically have a different mutation. It used to be thought that KRAS was “undruggable.” Maybe not. This sounds like a breakthrough.